Navigation Links
The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
Date:11/9/2010

BURLINGTON, Mass., Nov. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute ischemic stroke (AIS) drug market will remain relatively flat, increasing from $460 million in 2009 to approximately $610 million in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Acute Ischemic Stroke reveal that, in the forecasted absence of new therapies, drug-treatment rates in AIS will grow modestly as the use of recombinant tissue plasminogen activator (rt-PA; Genentech's Activase, other brands) gradually increases, aided by a recently extended treatment window. Rt-PA, the gold standard of pharmacological treatment in AIS, is administered to only a small fraction (less than 4 percent in 2009) of diagnosed patients in the world's major pharmaceutical markets.

"Broadening the use of rt-PA and interventional therapies such as stroke devices, including Concentric Medical's Merci Retrieval System, coupled with continued improvements in stroke systems of care will be crucial steps in the near-term future of stroke treatment," said Decision Resources Analyst Jonathan Searles. "Given the lingering questions among interviewed thought leaders about mid- and late-stage emerging treatments such as Paion/Lundbeck's thrombolytic desmoteplase and D-Pharm's metal ion chelator DP-b99, and in light of the continual attrition of investigational treatments in stroke, we do not forecast the launch of any novel therapies through 2019, although we continue to monitor several new therapies with great interest."

The findings also reveal that the persistent failure of neuroprotectants in clinical trials underscores physicians' growing skepticism about the promise of acute neuroprotection, particularly in monotherapy. Interviewed neurologists indicate that new directions in neurorestor
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
2. Cheetah Medicals NICOM(R) System for Noninvasive Hemodynamic Monitoring Found to be an Effective Tool for Identification of Acute Heart Failure in the Emergency Department
3. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
4. Awarepoint to Present ZigBee-based Wireless Sensor Networks for Use in Acute Care Hospitals and Beyond at Mobile Health Expo Speaker Session
5. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
6. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
7. Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
8. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
9. Global Acute Coronary Syndrome Industry
10. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
11. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
... , , ENGLEWOOD CLIFFS, ... all regular body washes caused dry skin damage. Now, ... while cleansing with body wash. Current body washes actually damage ... to the loss of critical moisture. Recognizing skin lipids require ...
Cached Medicine Technology:Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 2Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 3Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 4
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 The ... nutrition school, is pleased to announce that Arianna Huffington has ... the curriculum of the Health Coach Training Program . ... The Huffington Post, a world-renowned news and blogging site that ... is the author of fourteen books and was included on ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 Frozen shoulder ... are more likely to develop this nasty condition which occurs ... 60, and can last up to two and half years ... as frozen shoulder, and with good reason: it can render ... shirt — that is, if you aren't in too much ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... in a garden might help soothe the agitation that commonly ... at 17 past studies, British researchers found evidence that watering ... soothe some dementia patients, anxiety. The study authors cautioned ... tough subject to study -- and the evidence of a ...
(Date:7/30/2014)... three months or more as babies have a ... cardiovascular and metabolic diseases, according to research from ... Louis. , "This study shows that birthweight and ... later," said Molly W. Metzger, PhD, assistant professor ... the study with Thomas W. McDade, PhD, of ...
(Date:7/30/2014)... Lauderdale, FL (PRWEB) July 30, 2014 Everyone ... and communication for basically everyone. Whether people are looking for ... for something like a dentist, the internet is pretty much ... precisely why Sierra Dental in Lauderdale Florida is so happy ... will bring their web presence into the modern age. Whether ...
Breaking Medicine News(10 mins):Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2
... URAC CEO joins company along with ... Chief Medical Officer, ANNAPOLIS, Md., ... management leaders to head the,growing healthcare consulting and technology company. Senior management ... -- Joel V. Brill, MD, AGAF FASGE FACG CHCQM, Chief Medical ...
... Philadelphia, PA, September 20, 2007 Mark Twain boasted that it ... We now may have the beginnings of understanding why some ... are in treatment for this problem. According to statistics provided ... is the leading preventable cause of death in the United States, ...
... save years in research that aligns patients ... Fla., Sept. 20 The,H. Lee Moffitt ... Azyxxi(R),the Microsoft(R) unified health enterprise platform, to ... programs. Azyxxi will be used,to assimilate large ...
... Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation,(Nasdaq: DRRX ... CEO, will,present at the UBS Global Life Sciences ... 1:30 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ... presentation will be available by accessing,DURECT,s homepage at ...
... Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today announced that ... notional principal amount of its,6.5% senior convertible promissory notes, ... purchase warrants. This sale was effected as the,initial part ... in the,aggregate notional principal amount of up to $5 ...
... Childrens Hospital of Pittsburgh of UPMC psychiatrist Eva M. Szigethy, ... have been chosen by the director of the National Institutes ... , NIH director Elias A. Zerhouni, MD, announced today that ... in the early stages of their careers, including Dr. Szigethy ...
Cached Medicine News:Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Genetic variation affects smoking cessation treatment 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Children's Hospital of Pittsburgh psychiatrist receives prestigious NIH award 2
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
... The current available techniques for prenatal diagnosis ... with their use a small but significant ... current standard care offers invasive prenatal baby ... risk of chromosomal or genetic abnormalities are ...
Custom Pediatric Nebulizer Assembly W/Tubing...
... the only HER-2 assessment test approved by ... for three claims: prognosis, adriamycin-based chemotherapy selection ... PathVysion is the only FISH-based DNA probe ... insert as an appropriate test to aid ...
Medicine Products: